Skip to main content
. 2001 Sep 15;108(6):917–927. doi: 10.1172/JCI11564

Figure 9.

Figure 9

Cross-protective immunity of AdMDC-modified DCs against laboratory or clinical strains of P. aeruginosa. (a and b) Immunization resulting from AdMDC-modified DCs pulsed with laboratory strains of Pseudomonas. C57BL/6 mice were immunized with AdMDC-modified DCs pulsed with heat-killed P. aeruginosa laboratory strains PAO1, PAO-NP, PAK, or PA103 at 105 DCs per mouse. Three weeks after immunization, mice were challenged intratracheally with 2 × 105 CFU P. aeruginosa laboratory PAO1 strain (a) or clinical PA514 strain (b) enmeshed in agar beads. (c and d) Immunization resulting from AdMDC-modified DCs pulsed with clinical strains of Pseudomonas. C57BL/6 mice were immunized with AdMDC-modified DCs pulsed with heat-killed P. aeruginosa clinical strains PA514, PA515, PA516, or PA517 at 105 DCs per mouse. Three weeks after immunization, mice were challenged intratracheally with 2 × 105 CFU P. aeruginosa laboratory PAO1 strain (d) or clinical PA514 strain (c) enmeshed in agar beads. In all parts, controls included naive mice without any immunization. Survival was recorded as the percentage of surviving animals (n = 10 mice per group).